Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Cryopreserved-thawed embryos are often replaced in an artificial cycle, in which the endometrium is prepared by exogenous estrogen and progesterone with or without the use of GnRH agonist downregulation. The correct duration for exposure to progesterone is still not well established. To date, there are no prospective randomized trials available, comparing different durations of progesterone supplementation before the date of transfer, with regard to treatment outcome (Nawroth).

In this trial, the investigators want to determine the optimal duration of progesterone supplementation: 3 or 5 days before embryo transfer.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Universitair Ziekenhuis Brussel
• Treatments: Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Estrogens; Polyestradiol phosphate; Progesterone

Criteria

Inclusion Criteria:

• Artificial cycles, in which a frozen-thawed day 3 embryo is replaced.

• Signed informed consent.

• Normal transvaginal ultrasound at screening, without evidence of clinically significant abnormality consistent with finding adequate for ART with respect to uterus and adnexa.

• Embryos must be frozen by vitrification technique (cfr supra).

• Single or dual embryo transfer.

• Recipients of oocyte donation cycles may be included.

Exclusion Criteria:

• Known allergic reactions to progesterone products.

• Intake of experimental drug within 30 days prior to study start.

• Contraindication for pregnancy.

• Embryos of women above 39 years of age at the time of embryo freezing.